** Canadian drugmaker's shares continue to fall for the second day; U.S.-listed stock down 9.7 pct at $192.33
** Toronto-traded shares down 9.7 pct at C$192.15
** Company predicted on Monday that lower price increases are ahead for the whole industry
** "I do think, given that environment, the pricing that pharmaceutical companies will take in the future will be more modest," CEO Michael Pearson said
** Valeant and others have been criticized for acquiring companies and raising prices of drugs to boost profits
** Susquehanna cuts Valeant PT to $220 from $300, BMO cuts to $265 from $273
** CIBC cuts rating to "sector performer" from "outperformer", PT to $200
** Median PT is $250; 17 analysts rate stock "buy" and above, 5 "hold", 1 "sell"